Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

Swedish (OMX) Healthcare Sector Analysis

UpdatedMar 19, 2026
DataAggregated Company Financials
Companies150
  • 7D-1.4%
  • 3M-4.9%
  • 1Y-7.0%
  • YTD-5.7%

Over the last 7 days, the Healthcare industry has dropped 1.4%, driven by Swedish Orphan Biovitrum declining 3.1%. However, the industry is down 7.0% over the past year. As for the next few years, earnings are expected to grow by 25% per annum.

Sector Valuation and Performance

Has the Swedish Healthcare Sector valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Thu, 19 Mar 2026SEK 550.2bSEK 228.8b-SEK 2,896,686,591.9730.7x-189.9x2.4x
Sat, 14 Feb 2026SEK 565.4bSEK 230.9b-SEK 1,751,199,327.3530.8x-322.8x2.4x
Mon, 12 Jan 2026SEK 599.8bSEK 230.2bSEK 3.7b41x163.5x2.6x
Wed, 10 Dec 2025SEK 582.0bSEK 230.6bSEK 3.5b41.2x164.2x2.5x
Fri, 07 Nov 2025SEK 588.5bSEK 229.2bSEK 2.8b45.4x212.8x2.6x
Sun, 05 Oct 2025SEK 614.1bSEK 227.1bSEK 6.6b43.2x93x2.7x
Tue, 02 Sep 2025SEK 623.8bSEK 227.1bSEK 6.6b46.1x94.7x2.7x
Thu, 31 Jul 2025SEK 632.0bSEK 226.9bSEK 6.5b54.1x96.6x2.8x
Sat, 28 Jun 2025SEK 616.8bSEK 226.8bSEK 5.9b44.9x105.1x2.7x
Mon, 26 May 2025SEK 587.3bSEK 226.0bSEK 6.6b37x89.3x2.6x
Wed, 23 Apr 2025SEK 549.9bSEK 222.1bSEK 5.0b37.5x110.7x2.5x
Fri, 21 Mar 2025SEK 558.9bSEK 206.3bSEK 5.0b37x112x2.7x
Sun, 16 Feb 2025SEK 594.9bSEK 206.4bSEK 2.5b41.7x236.5x2.9x
Tue, 14 Jan 2025SEK 571.2bSEK 201.6b-SEK 2,648,325,362.5039.2x-215.7x2.8x
Thu, 12 Dec 2024SEK 575.6bSEK 202.8b-SEK 2,465,020,947.5338.6x-233.5x2.8x
Sat, 09 Nov 2024SEK 528.5bSEK 200.2b-SEK 2,597,706,631.9538.6x-203.4x2.6x
Mon, 07 Oct 2024SEK 607.5bSEK 200.2b-SEK 2,782,910,611.7639.8x-218.3x3x
Wed, 04 Sep 2024SEK 607.0bSEK 200.0b-SEK 2,809,391,402.8740x-216.1x3x
Fri, 02 Aug 2024SEK 584.7bSEK 199.7b-SEK 2,762,785,972.7841.1x-211.6x2.9x
Sun, 30 Jun 2024SEK 562.0bSEK 195.7b-SEK 3,202,643,667.9236.8x-175.5x2.9x
Tue, 28 May 2024SEK 552.0bSEK 196.0b-SEK 2,798,220,083.8936.2x-197.3x2.8x
Thu, 25 Apr 2024SEK 521.0bSEK 194.1b-SEK 3,331,281,004.7543.9x-156.4x2.7x
Sat, 23 Mar 2024SEK 519.8bSEK 192.7b-SEK 3,669,066,937.9843.3x-141.7x2.7x
Mon, 19 Feb 2024SEK 516.9bSEK 191.7b-SEK 4,080,444,504.7249.9x-126.7x2.7x
Wed, 17 Jan 2024SEK 551.4bSEK 191.7b-SEK 967,683,823.0048.2x-569.8x2.9x
Fri, 15 Dec 2023SEK 517.8bSEK 191.2b-SEK 999,563,618.0048.9x-518x2.7x
Sun, 12 Nov 2023SEK 470.7bSEK 190.4b-SEK 1,080,492,686.0049.4x-435.7x2.5x
Tue, 10 Oct 2023SEK 439.1bSEK 185.1b-SEK 2,032,014,505.0033.8x-216.1x2.4x
Thu, 07 Sep 2023SEK 457.1bSEK 185.8b-SEK 2,013,608,879.0035.8x-227x2.5x
Sat, 05 Aug 2023SEK 473.1bSEK 183.9b-SEK 1,003,843,769.0039.9x-471.3x2.6x
Mon, 03 Jul 2023SEK 480.3bSEK 179.2b-SEK 793,306,793.0044.7x-605.5x2.7x
Wed, 31 May 2023SEK 504.9bSEK 178.9b-SEK 549,905,700.0043.5x-918.2x2.8x
Fri, 28 Apr 2023SEK 513.3bSEK 174.8b-SEK 1,487,139,903.0035.1x-345.1x2.9x
Sun, 26 Mar 2023SEK 482.3bSEK 172.4b-SEK 1,417,086,752.0035.3x-340.4x2.8x
Price to Earnings Ratio

-340.4x


Total Market Cap: SEK 482.3bTotal Earnings: -SEK 1,417,086,752.00Total Revenue: SEK 172.4bTotal Market Cap vs Earnings and Revenue0%0%0%
Swedish Healthcare Sector Price to Earnings3Y Average -165.9x202420252026
Current Industry PE
  • Investors are pessimistic on the Swedish Healthcare industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The 3-year average PS ratio of 2.7x is higher than the industry's current PS ratio of 2.4x.
Past Earnings Growth
  • The earnings for companies in the Healthcare industry have deteriorated over the last three years.
  • Meanwhile revenues for these companies have grown 9.9% per year.
  • This means that although more sales are being generated, either the cost of doing business or the level of investment back into businesses has increased, which has caused losses to expand.

Industry Trends

Which industries have driven the changes within the Swedish Healthcare sector?

SE Market-1.35%
Healthcare-1.36%
Healthtech1.99%
Pharma-0.72%
Medical Equipment-1.00%
Life Sciences-1.49%
Healthcare Services-1.59%
Biotech-2.38%
Industry PE
  • Investors are most optimistic about the Healthtech industry which is trading above its 3-year average PE ratio of 115x.
    • Analysts are expecting annual earnings growth of 20.2%, which is higher than its past year's earnings growth of 1.5% per year.
Forecasted Growth
  • Analysts are most optimistic on the Pharma industry, expecting annual earnings growth of 35% over the next 5 years.
  • This is better than its past earnings growth rate of 14% per year.
  • In contrast, the Life Sciences industry is expected to see its earnings grow by 17% per year over the next few years.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
BIOG B BioGaiaSEK 113.602.8%
+SEK 313.6m		-2.5%PE34.5x
SECT B SectraSEK 229.400.7%
+SEK 308.3m		-9.9%PE82.2x
VIMIAN Vimian GroupSEK 25.962.3%
+SEK 307.0m		-34.8%PE40.8x
DICOT Dicot PharmaSEK 0.4421.2%
+SEK 153.7m		63.4%PB12x
FLERIE FlerieSEK 35.055.4%
+SEK 148.1m		-22.4%PS1116.6x

Latest News

CRNO B
SEK 6.00
Cereno Scientific
7D
3.6%
1Y
14.6%
SOBI
SEK 362.40
Swedish Orphan Biovitrum
7D
-4.4%
1Y
23.2%
FLUO
SEK 37.60
FluoGuide
7D
23.3%
1Y
-7.7%
CAMX
SEK 458.00
Camurus
7D
-2.7%
1Y
-25.9%

CAMX: 2026 Guidance And US FDA Review Will Drive Future Upside

Analysts have kept their SEK 930 price target for Camurus unchanged, citing only minor adjustments in their assumptions for revenue growth, profit margin and future P/E as the main reasons for maintaining this level. What's in the News Camurus issued earnings guidance for 2026, with expected revenues of SEK 2.6b to SEK 2.9b and an operating result of SEK 0.9b to SEK 1.2b (Corporate guidance).
VITR
SEK 87.95
Vitrolife
7D
-5.0%
1Y
-48.1%
BONEX
SEK 178.90
Bonesupport Holding
7D
-8.0%
1Y
-45.7%

Slow Trauma Center Adoption And Regulatory Hurdles Will Eventually Support A Healthier Business Mix

Catalysts About Bonesupport Holding Bonesupport Holding develops and sells CERAMENT bone void fillers, including antibiotic eluting products used to treat complex bone infections and defects. What are the underlying business or industry changes driving this perspective?
GETI B
SEK 182.50
Getinge
7D
-4.1%
1Y
-17.9%

GETI B: Slightly Higher Dividend Will Still Leave P/E Looking Stretched

Analysts have kept their SEK 170.97 price target for Getinge broadly unchanged, citing only marginal tweaks to assumptions around the discount rate, revenue growth, profit margin and future P/E that do not materially alter their overall view of the shares. What's in the News Getinge AB has a proposed dividend of SEK 4.75 per share, compared with SEK 4.60 previously (Key Developments).
FLERIE
SEK 35.05
Flerie
7D
5.4%
1Y
-22.4%
SECT B
SEK 229.40
Sectra
7D
0.7%
1Y
-9.9%
MCOV B
SEK 195.60
Medicover
7D
-4.8%
1Y
-2.9%

MCOV B: Dividend Uplift And 2028 Revenue Ambition Will Support Future Upside

Analysts have kept their price target for Medicover broadly unchanged at around SEK 257, reflecting stable assumptions on the discount rate, revenue growth, profit margin and future P/E multiples. What's in the News The board of Medicover AB proposes a dividend of SEK 0.20 per share for the financial year 2025, compared with SEK 0.15 previously, subject to approval at the annual general meeting on 29 April 2026 (Key Developments).
BIOG B
SEK 113.60
BioGaia
7D
2.8%
1Y
-2.5%

BIOG B: Extra Dividend And Solid Margins Will Support Higher Earnings Multiple

Analysts have maintained their SEK 140.0 fair value estimate for BioGaia, citing only minor adjustments to the discount rate and to long-term assumptions on revenue growth, profit margins and future P/E as the basis for keeping their price target unchanged. What's in the News BioGaia renewed and extended its distribution agreement with Ewopharma, which will now distribute a broad range of BioGaia products in more than 15 European countries, with a focus on Central Eastern Europe and Switzerland (Key Developments).
VIMIAN
SEK 25.96
Vimian Group
7D
2.3%
1Y
-34.8%

VIMIAN: Reduced Price Outlook And Execution Risks Will Shape Fairly Balanced Prospects

Analysts have lowered their price target on Vimian Group to SEK 25 from SEK 27, reflecting updated assumptions for fair value, discount rate, revenue growth, profit margin and future P/E multiples. Analyst Commentary Bearish analysts have trimmed their fair value assumptions for Vimian Group, as seen in the reduced price target to SEK 25 from SEK 27.
ALIF B
SEK 138.10
AddLife
7D
-2.7%
1Y
-7.1%
ASKER
SEK 64.30
Asker Healthcare Group
7D
-2.6%
1Y
n/a
DICOT
SEK 0.44
Dicot Pharma
7D
21.2%
1Y
63.4%

Is Dicot Pharma (STO:DICOT) In A Good Position To Invest In Growth?

Feb 03
Is Dicot Pharma (STO:DICOT) In A Good Position To Invest In Growth?
HAMLET B
SEK 4.20
Hamlet BioPharma
7D
14.3%
1Y
1.4%